At first glance Veru, Inc.’s (NASDAQ: VERU) COVID-19 therapy phase 3 top line results were notable but their battle for an emergency...
It’s abundantly clear that there is a large short interest in CytoDyn Inc. (OTCMKTS: CYDY). The bear biotech analyst Adam Feuerstein recently...
CytoDyn Inc (OTCMKT: CYDY) has been under considerable selling pressure since April and nothing seems to be able to stop it. In...
The big news circulating this week was of Atea Pharmaceuticals’ (NASDAQ: AVIR) COVID-19 antiviral clinical trial failure, which instantly plummeted the stock...
Shares of Moderna (NASDAQ: MRNA) recently spiked over $400, giving the mRNA vaccine maker a market cap of about $200 billion, greater...
Short attack timed to capitalize on consolidation and thin trading The Oregonian misquotes and twists statements taken out of context SEC case...
CytoDyn Inc. (OTCMKTS: CYDY) announced excellent preliminary results from its Phase 1b/2 clinical trial in metastatic triple negative breast cancer...
Latest 8-K filing settles dispute for $7.6 million but paves way for Pestell share repurchase at par 13-D Group is outspoken but...
CytoDyn Inc (OTCMKTS: CYDY) shareholders got a real gut check yesterday as the STAT writer Adam Feuerstein sent out a tweet at...
Many CytoDyn Inc. (OTCMKTS: CYDY) shareholders have been waiting impatiently for an EUA from the US FDA and a BLA in HIV. ...